Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
56 studies found for:    MACULAR DYSTROPHY, RETINAL, 3
Show Display Options
Rank Status Study
1 Recruiting Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration
Conditions: Exudative Macular Degeneration;   Retinal Hemorrhage
Interventions: Drug: Ranibizumab;   Drug: C3F8 Gas;   Drug: tPA
2 Recruiting Retinal Therapy Guided by 3D OCT Image Analysis
Conditions: Age-Related Macular Degeneration;   Choroidal Neovascularization
Intervention:
3 Not yet recruiting Microperimetry and Eye Progressing From Stage 3 to Stage 4 Age-related Macular Degeneration (AMD)
Condition: Stage 3 Age Related Macular Degeneration (AREDS Classification)
Intervention: Device: MAIA™ (Centrevue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)
4 Unknown  Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration
Condition: Macular Degeneration
Intervention: Dietary Supplement: Omega-3 fatty acid
5 Terminated Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).
Condition: Age-related Macular Degeneration
Intervention:
6 Active, not recruiting Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)
Condition: Age-related Macular Degeneration
Interventions: Drug: Omega-3 fatty acids (fish oil);   Dietary Supplement: Vitamin D3;   Dietary Supplement: Vitamin D3 placebo;   Dietary Supplement: Fish oil placebo
7 Completed Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Condition: Age-Related Macular Degeneration
Intervention: Drug: pegaptanib sodium (Macugen)
8 Recruiting A Phase 2/3 Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura® (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Conditions: Geographic Atrophy;   Macular Degeneration
Interventions: Drug: Zimura®;   Drug: Sham
9 Active, not recruiting Study of Intravitreal REGN2176-3 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
Condition: Neovascular Age-Related Macular Degeneration
Interventions: Drug: REGN2176-3;   Drug: Intravitreal Aflibercept Injection (IAI)
10 Recruiting Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: NT-503-3 ECT implantation;   Drug: Eylea® injected intravitreally administered every 8 weeks
11 Completed Omega-3-fatty Acids on Age-related Macular
Condition: Aged Macular Degeneration
Interventions: Dietary Supplement: Omega 3;   Other: Olive Oil
12 Completed Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
Conditions: Neovascular Age-Related Macular Degeneration;   Diabetic Macular Edema
Interventions: Drug: REGN910-3;   Drug: REGN910;   Drug: Intravitreal Aflibercept Injection (IAI)
13 Completed Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
Condition: Macular Degeneration
Interventions: Drug: Anecortave Acetate 15 mg sterile suspension;   Other: Photodynamic Therapy (PDT)
14 Recruiting A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: ranibizumab;   Drug: E10030 sham intravitreal injection
15 Active, not recruiting A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: ranibizumab;   Drug: E10030 sham intravitreal injection
16 Recruiting A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: bevacizumab or aflibercept;   Drug: E10030 sham intravitreal injection
17 Completed Consumption of Eggs Rich in Lutein and Omega-3 Fatty Acids on the Macular Pigment
Condition: Age-related Macular Degeneration
Intervention: Other: Nutritional study
18 Completed Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60
Condition: Macular Degeneration
Intervention: Drug: Lutein
19 Completed
Has Results
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: Ranibizumab;   Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
20 Completed
Has Results
Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
Condition: Exudative Age-related Macular Degeneration.
Interventions: Dietary Supplement: Anti-VEGF plus AREDS-2;   Dietary Supplement: Anti-VEGF plus AREDS-1

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years